OneMedNet Signs Global Pharmaceutical Intelligence Provider as Channel Partner, Extending Reach in Pharma Market
Key Highlights
- ➤12th channel partnership expands OneMedNet’s pharmaceutical-market distribution reach
- ➤Global pharmaceutical intelligence provider will distribute OneMedNet’s U.S.-sourced clinical data worldwide
- ➤Real-World Data market estimated at $2.7B in 2026, projected to reach $7.1B by 2033
- ➤OneMedNet network spans 2,300-plus sites, 90 million patient journeys, and 270 million studies
Expert Statements
Aaron Green, President & CEO of OneMedNet
“We believe our channel partners choose OneMedNet for the same reason end customers do: data that comes straight from the source”
Aaron Green, President & CEO of OneMedNet
“First-party, direct-from-source data gives our partners confidence in the quality, provenance, and compliance of what they deliver to their customers.”
Aaron Green, President & CEO of OneMedNet
“This partnership expands our reach in the pharmaceutical market.”
MINNEAPOLIS, Oct. 19, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of First-Party (Direct-from-Source) regulatory decision-grade, AI-driven Real-World Data (RWD), today announced its 12th channel partner agreement, under which a leading global provider of pharmaceutical intelligence and data solutions will distribute OneMedNet’s U.S.-sourced, de-identified clinical data to its established base of pharmaceutical customers worldwide. The agreement broadens OneMedNet’s reach into one of the fastest-growing segments of life sciences data. The global Real-World Data market is estimated at approximately US$2.7 billion in 2026 and is projected to reach US$7.1 billion by 2033, according to Coherent Market Insights(1), as pharmaceutical companies increasingly rely on Real-World Data to support drug development, regulatory submissions, and commercial decisions.
Get started
Create a free account to read the full story.